Trajectories of daily antipsychotic use and weight gain in people hospitalized for the first episode of psychosis

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F24%3A43921329" target="_blank" >RIV/00023752:_____/24:43921329 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11120/24:43927596

Result on the web

<a href="https://www.cambridge.org/core/journals/european-psychiatry/article/trajectories-of-daily-antipsychotic-use-and-weight-gain-in-people-hospitalized-for-the-first-episode-of-psychosis/5824D9F54E97FD375F533F9B4EC46B50" target="_blank" >https://www.cambridge.org/core/journals/european-psychiatry/article/trajectories-of-daily-antipsychotic-use-and-weight-gain-in-people-hospitalized-for-the-first-episode-of-psychosis/5824D9F54E97FD375F533F9B4EC46B50</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1192/j.eurpsy.2024.1761" target="_blank" >10.1192/j.eurpsy.2024.1761</a>

Result language

angličtina

Original language name

Trajectories of daily antipsychotic use and weight gain in people hospitalized for the first episode of psychosis

Original language description

Background We need to better understand the risk factors and predictors of medication-related weight gain to improve metabolic health of individuals with schizophrenia. This study explores how trajectories of antipsychotic medication (AP) use impact body weight early in the course of schizophrenia.Methods We recruited 92 participants with first-episode psychosis (FEP, n = 92) during their first psychiatric hospitalization. We prospectively collected weight, body mass index (BMI), metabolic markers, and exact daily medication exposure during 6-week hospitalization. We quantified the trajectory of AP medication changes and AP polypharmacy using a novel approach based on meta-analytical ranking of medications and tested it as a predictor of weight gain together with traditional risk factors.Results Most people started treatment with risperidone (n = 57), followed by olanzapine (n = 29). Then, 48% of individuals remained on their first prescribed medication, while 33% of people remained on monotherapy. Almost half of the individuals (39/92) experienced escalation of medications, mostly switch to AP polypharmacy (90%). Only baseline BMI was a predictor of BMI change. Individuals in the top tercile of weight gain, compared to those in the bottom tercile, showed lower follow-up symptoms, a trend for longer prehospitalization antipsychotic treatment, and greater exposure to metabolically problematic medications.Conclusions Early in the course of illness, during inpatient treatment, baseline BMI is the strongest and earliest predictor of weight gain on APs and is a better predictor than type of medication, polypharmacy, or medication switches. Baseline BMI predicted weight change over a period of weeks, when other traditional predictors demonstrated a much smaller effect.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30215 - Psychiatry

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

European Psychiatry

ISSN

0924-9338

e-ISSN

1778-3585

Volume of the periodical

67

Issue of the periodical within the volume

1

Country of publishing house

FR - FRANCE

Number of pages

9

Pages from-to

"e59"

UT code for WoS article

001319563400001

EID of the result in the Scopus database

2-s2.0-85204941253